Trial Profile
Descriptive Study Comparing Regadenoson Versus Dipyridamole in Use as Pharmacological Stress Agent Before a Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (SPECT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Dipyridamole (Primary) ; Regadenoson (Primary)
- Indications Coronary disorders
- Focus Therapeutic Use
- Acronyms REDUCE
- 12 Apr 2018 Status changed from recruiting to completed.
- 11 May 2017 Planned End Date changed from 1 Nov 2017 to 3 Feb 2018.
- 11 May 2017 Planned primary completion date changed from 1 Oct 2017 to 3 Jan 2018.